Where Does DaVita Stock Rank Among Competitors?
DaVita‘s stock has underperformed over the past year, as of 2/3/2026. How does DVA truly measure up against healthcare peers like HCA and EHC? A closer look reveals strong profitability and solid free cash flow generation. However, its revenue growth trails some rivals, contributing to a more moderate valuation. Upside may be constrained if faster-scaling peers continue to gain momentum.
- DVA’s 14.6% operating margin, strong yet below EHC’s 17.3%, signals higher reimbursement from complex cases for EHC versus DVA’s regulated dialysis market.
- DVA’s 5.1% revenue growth, outpacing CYH but trailing HCA/EHC, reflects dialysis volume pressures vs. hospital/post-acute patient/tech-driven expansion.
- DVA’s 23.9% stock decline, underperforming peers with a 12.6 PE, reflects dialysis market headwinds from drug innovations and rising costs.
Here’s how DaVita stacks up across size, valuation, and profitability versus key peers.
| DVA | HCA | EHC | SEM | CYH | PRVA | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 9.7 | 116.3 | 9.5 | 1.8 | 0.4 | 2.8 |
| Revenue ($ Bil) | 13.3 | 74.4 | 5.8 | 5.4 | 12.6 | 2.0 |
| PE Ratio | 12.6 | 18.3 | 17.5 | 16.5 | 1.3 | 151.6 |
| LTM Revenue Growth | 5.1% | 6.8% | 11.1% | 45.3% | 0.7% | 19.0% |
| LTM Operating Margin | 14.6% | 15.6% | 17.3% | 5.5% | 8.6% | 1.4% |
| LTM FCF Margin | 9.7% | 10.9% | 6.9% | 3.2% | 1.1% | 5.4% |
| 12M Market Return | -23.9% | 50.4% | -5.6% | -24.0% | -1.6% | -2.0% |
For more details on DaVita, read Buy or Sell DVA Stock. Below we compare DVA’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- AI Won’t Kill Software. Here’s How To Hunt For Value
- What Could Rocket Alphabet Stock to New Heights
- The Hidden Dangers Facing Micron Technology Stock
- Cash Machine Trading Cheap – Docusign Stock Set to Run?
- Micron Technology Stock On A Winning Streak: Time To Get In Or Book Profits?
- Is Microsoft Stock Poised for a Rally?
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| DVA | 5.1% | 5.6% | 4.6% | -0.1% |
| HCA | 6.8% | 8.7% | 7.9% | 2.5% |
| EHC | 11.1% | 11.9% | 10.4% | 8.3% |
| SEM | 45.3% | 7.5% | 4.7% | -25.7% |
| CYH | 0.7% | 1.2% | 2.3% | -1.3% |
| PRVA | 19.0% | 4.7% | 22.2% | 40.4% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| DVA | 14.6% | 15.3% | 13.2% | 11.3% |
| HCA | 15.6% | 14.9% | 14.8% | 15.0% |
| EHC | 17.3% | 16.1% | 15.2% | 14.5% |
| SEM | 5.5% | 5.2% | 5.5% | 3.1% |
| CYH | 8.6% | 6.7% | 7.0% | 5.9% |
| PRVA | 1.4% | 1.0% | 1.2% | -1.4% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| DVA | 12.6 | 10.3 | 19.6 | 17.4 |
| HCA | 18.3 | 21.0 | 15.6 | 13.9 |
| EHC | 17.5 | 23.3 | 26.1 | 24.4 |
| SEM | 16.5 | 8.6 | 9.5 | 18.4 |
| CYH | 1.3 | -0.8 | -2.9 | 8.8 |
| PRVA | 151.6 | 196.8 | 98.9 | -296.9 |
Still not sure about DVA stock? Consider portfolio approach.
Portfolios Win When Stock Picks Fall Short
Individual picks can be volatile but staying invested is what matters. A diversified portfolio helps you stay the course, capture upside and reduce downside
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.